Ignasi Rodriguez Pintó, Spain

Hospital Universitari Mutua de Terrassa Internal Medicine
My interest in science dates back to my years in high school, where I excelled in biology, physics, chemistry and mathematics. My love for science was one of my reasons for choosing medicine. I have enjoyed the challenge of becoming a doctor and actually it has been extremely gratifying. As an undergraduate, I had the opportunity to work as Internal Alumni at the Anatomy Department during the first 2 years and at the Pathology Department afterwards, where I was able to improve my technical skills in the laboratory of molecular biology. I was qualified in Medicine in 2004 by the Universitat Autònoma de Barcelona. After that, I performed my residency at Hospital Universitari Parc de Salut Mar in Barcelona. During my last year of residency, due to my high interest in autoimmune diseases, I performed a clinical stage in the Autoimmune Disease Unit in the Hospital Universitari de la Vall d’Hebron. In the Unit I was able to face these patients from the beginning of my medical training. At the same time, I also took the Master of Autoimmune Disease at the Universitat de Barcelona directed by Dr. Prof. Ricard Cervera. This great experience took me to volunteer at the Autoimmune Disease Department of Hospital Clinic where I became a fellow on 2012. At this Department I have the exciting experience of attending patients with autoimmune disease and especially with Antiphospholipid Syndrome. At the end of the Master of Autoimmune Disease I became the data manager of the Catastrophic Antiphospholipid Syndrome Registry and I have been in charge of its update since then. My special interest in research on this field motivated me to perform the Master of Methodology of Investigation provided by Universitat Autònoma de Barcelona and directed by Dr. Prof. Domènech from 2011 to 2013. I succeeded with very high qualifications. Thanks to it, I improved my skills in statistics and database construction and became a reference for many of my colleges at the department. In 2018, I was graduated in Ph.D on the Catastrophic Antiphospholipid Syndrome with “cum laude” and international mention distinction. My research activity focused mostly on the Catastrophic Antiphospholipid Syndrome is documented by papers on prestigious national and international journals in which I am the author or co-author.

Presenter of 1 Presentation

EFFICACY OF ECULIZUMAB IN CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: DESCRIPTIVE ANALYSIS FROM THE “CAPS REGISTRY

Session Type
PARALLEL SESSIONS
Date
30.05.2021, Sunday
Session Time
10:00 - 12:00
Room
HALL G
Lecture Time
11:00 - 11:10
Session Icon
Pre Recorded

Abstract

Background and Aims

To assess the efficacy of eculizumab in patients with catastrophic antiphospholipid syndrome (CAPS) based on the real-world experience provided by the “CAPS Registry”.

Methods

We analyzed demographic, clinical and immunological data from all the patients included in the “CAPS Registry” treated with eculizumab and additionally we described eculizumab indication, dose, outcome, use of prophylactic vaccines and adverse effects.

Results

The “CAPS Registry” includes 563 patients from whom 21 (3.7%) were treated with eculizumab (mean age 42.1 years (SD=15); 81.0% female; primary APS patients, 71.4%; precipitating factors, 57.1%): Sixteen (76.1%) of them recovered from the episode of CAPS, 4 (19.0%) patients died, and one (4.7%) patient did not show any improvement with eculizumab. There were no recurrences of thrombosis after a median follow up of 10.7 months. Different regimens were used, but the most common was 900mg weekly for four weeks and 1200mg fortnightly. The required duration of treatment remains unclear.

Conclusions

According to the published evidence and our observations, we consider that eculizumab can be used in addition to the standard treatment as an alternative in patients with CAPS.

Hide